Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions? Observations and introspection of the bioanalysis
Disha Thakkar,1 Ranjeet Prasad Dash2,3
1Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research-Ahmedabad, Gandhinagar, Gujarat, India; 2Drug Metabolism and Pharmacokinetics, Johns Hopkins Drug Discovery Program, Johns Hopkins University, 3Department of Neurology, Johns Hopkins University, Baltimore, MD, USA
The topic of polymorphism in drug metabolizing enzymes and drug transporters with their impact on pharmacotherapy is of great interest. The clinical relevance depends on the vectorial movement, the therapeutic index of the substrates and inherent interindividual variability.1 With respect to the variability, various polymorphisms associated with the drug transporters have been reported that led to the alteration in the pharmacokinetic and pharmacodynamic profile of the drugs.2 Many preclinical and clinical studies have provided the evidence for the application of genetic information for the development of individualized therapies.3
View the original paper by Kim CO and colleagues.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]